Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 8/20 | 0.43 |
| ▸ | EDNRA | P25101 | 8/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | PPIA | P62937 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8087901 | 0.83 | MEN1 (0.52) | CYP1A2MAPK1EDNRBEDNRAMEN1 | |
| SCHEMBL8087837 | 0.83 | MEN1 (0.52) | CYP1A2MAPK1EDNRBEDNRAMEN1 | |
| SCHEMBL19164428 | 0.81 | CYP1A2 (0.77) | CYP1A2MAPK1EDNRBEDNRAMAOB | |
| SCHEMBL27818578 | 0.74 | PPIA (0.43) | CYP1A2MAPK1PTPN1PPIAMAPT | |
| SCHEMBL7959774 | 0.74 | MAPK1 (0.44) | CYP1A2MAPK1EDNRBEDNRAMEN1 | |
| SCHEMBL19164165 | 0.74 | MAPK1 (0.62) | CYP1A2MAPK1EDNRBEDNRAMAOB | |
| SCHEMBL3894758 | 0.73 | MEN1 (0.57) | MAPK1PTPN1MAOBMEN1CDC25B | |
| SCHEMBL9765532 | 0.72 | S100A4 (0.50) | CYP1A2MAPK1PTPN1EDNRBEDNRA | |
| SCHEMBL181722 | 0.71 | PTPRC (0.55) | CYP1A2MAPK1PTPN1MAOBMEN1 | |
| SCHEMBL563010 | 0.71 | MEN1 (0.55) | CYP1A2MAPK1PTPN1MAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10476006-B2 | Compound and organic electronic device using the same | SHANGHAI NICHEM FINE CHEMICAL CO., LTD. (CN) | 2019-11-12 | — | — | US | disclosed |
| EP-3281936-B1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | SHANGHAI NICHEM FINE CHEMICAL CO LTD (CN) | 2019-10-09 | — | — | EP | disclosed |
| US-20180047908-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | NICHEM FINE TECHNOLOGY CO., LTD. (TW) | 2018-02-15 | — | — | US | disclosed |
| US-20180047908-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | NICHEM FINE TECHNOLOGY CO., LTD. (TW) | 2018-02-15 | — | — | US | disclosed |
| EP-3281936-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | Nichem Fine Technology Co., Ltd. (TW) | 2018-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10476006-B2 | Compound and organic electronic device using the same | ESR1, AOC2, PIEZO1 | CYP1A2 26/4885MAPK1 1080/4885PTPN1 2973/4885 |
| US-20180047908-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | ESR1, AOC2, PIEZO1 | CYP1A2 26/4885MAPK1 1080/4885PTPN1 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.